索宝蛋白(603231)：低位采购原料利润高增 新产能投产有望提升盈利能力

Core Viewpoint - The company is expected to achieve significant growth in net profit for 2025, with projections indicating a year-on-year increase of 46.89% to 57.62% for net profit attributable to shareholders, and 56.03% to 66.07% for net profit after deducting non-recurring gains and losses [1] Group 1: Financial Performance - For 2025, the company forecasts a net profit attributable to shareholders of 1.78 to 1.91 billion yuan, and a net profit after deducting non-recurring gains and losses of 1.71 to 1.82 billion yuan [1] - In Q4 2025, the company anticipates a net profit of 0.31 to 0.44 billion yuan, representing a year-on-year growth of 6.1% to 50.2% [1] - The projected revenue for 2025 to 2027 is 17.04 billion yuan, 18.63 billion yuan, and 22.66 billion yuan, with year-on-year growth rates of 9.53%, 9.36%, and 21.63% respectively [2] Group 2: Operational Strategy - The company focuses on high-end manufacturing, energy optimization, and lean management to achieve significant cost reductions and efficiency improvements [1] - The management team actively monitors raw material market trends to capitalize on procurement opportunities, effectively lowering the cost of non-GMO soybean procurement [1] - New high-margin production capacities are expected to come online by the end of 2026, contributing to revenue growth and improving product structure [1] Group 3: Future Projections - The company expects to launch a 30,000-ton soybean textured protein project and a high-end soybean protein production line by December 2026 and June 2027, respectively [1] - The new products, including textured protein and high-end soybean protein, are anticipated to have high profit margins, which will support revenue growth as production capacity is released [1] - The projected net profit for 2025 to 2027 is 1.85 billion yuan, 2.00 billion yuan, and 2.82 billion yuan, with respective year-on-year growth rates of 52.54%, 7.99%, and 41.34% [2]